Australia, New Zealand speed up OTC drug review
This article was originally published in SRA
As of 15 April, Australia and New Zealand will adopt a common administrative procedure for reviewing over-the-counter medicines that aims to shorten and make more predictable the time in which such products can reach the market1-3.
You may also be interested in...
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.